The Third Ward of Orthopaedic Department, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
Institute of Osteoarthropathy, Ningxia Key Laboratory of Clinical and Pathogenic Microbiology, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
Mol Cell Biol. 2024;44(10):411-428. doi: 10.1080/10985549.2024.2385633. Epub 2024 Aug 22.
Osteoarthritis (OA) is a chronic degenerative disease characterized by subchondral osteosclerosis, mainly due to osteoblast activity. This research investigates the function of Sik1, a member of the AMP-activated protein kinase family, in OA. Proteomic analysis was conducted on clinical samples from 30 OA patients, revealing a negative correlation between Sik1 expression and OA. In vitro experiments utilized BMSCs to examine the effect of Sik1 on osteogenic differentiation. BMSCs were cultured and induced toward osteogenesis with specific media. Sik1 overexpression was achieved through lentiviral transfection, followed by analysis of osteogenesis-associated proteins using Western blotting, RT-qPCR, and alkaline phosphate staining. In vivo experiments involved destabilizing the medial meniscus in mice to establish an OA model, assessing the therapeutic potential of Sik1. The CT scans and histological staining were used to analyze subchondral bone alterations and cartilage damage. The findings show that Sik1 downregulation correlates with advanced OA and heightened osteogenic differentiation in BMSCs. Sik1 overexpression inhibits osteogenesis-related markers in vitro and reduces cartilage damage and subchondral osteosclerosis in vivo. Mechanistically, Sik1 modulates osteogenesis and subchondral bone changes through Runx2 activity regulation. The research emphasizes Sik1 as a promising target for treating OA, suggesting its involvement in controlling bone formation and changes in the subchondral osteosclerosis.
骨关节炎(OA)是一种慢性退行性疾病,其特征为软骨下骨硬化,主要是由于成骨细胞活性增强所致。本研究探讨了 AMP 激活蛋白激酶家族成员 Sik1 在 OA 中的作用。对 30 名 OA 患者的临床样本进行蛋白质组学分析,结果表明 Sik1 的表达与 OA 呈负相关。体外实验利用骨髓间充质干细胞(BMSCs)研究 Sik1 对成骨分化的影响。将 BMSCs 培养并在特定培养基中诱导其向成骨细胞分化。通过慢病毒转染实现 Sik1 的过表达,然后使用 Western blot、RT-qPCR 和碱性磷酸酶染色分析成骨相关蛋白。体内实验通过破坏内侧半月板在小鼠中建立 OA 模型,评估 Sik1 的治疗潜力。通过 CT 扫描和组织学染色分析软骨下骨改变和软骨损伤。研究结果表明,Sik1 的下调与 OA 的进展和 BMSCs 中增强的成骨分化相关。Sik1 的过表达在体外抑制成骨相关标志物,并减少体内软骨损伤和软骨下骨硬化。机制上,Sik1 通过调节 Runx2 活性来调节成骨和软骨下骨变化。该研究强调了 Sik1 作为治疗 OA 的有前途的靶点,提示其参与控制骨形成和软骨下骨硬化的变化。